Elliot Goodfellow

St. Laurent
QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity.

The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity.

Journal: Research square

Published: August 06, 2025

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.

Journal: Nature communications

Published: July 06, 2025

Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor.

Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor.

Journal: Journal of medicinal chemistry

Published: May 16, 2025

MICAL2 Is a Super Enhancer Associated Gene that Promotes Pancreatic Cancer Growth and Metastasis.

MICAL2 Is a Super Enhancer Associated Gene that Promotes Pancreatic Cancer Growth and Metastasis.

Journal: bioRxiv : the preprint server for biology

Published: July 09, 2024

MICAL2 Promotes Pancreatic Cancer Growth and Metastasis.

MICAL2 Promotes Pancreatic Cancer Growth and Metastasis.

Journal: Cancer research

Published: March 04, 2024

Design and Synthesis of a Trifunctional Molecular System "Programmed" to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells.

Design and Synthesis of a Trifunctional Molecular System "Programmed" to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells.

Journal: Journal of medicinal chemistry

Published: June 03, 2020

Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules.

Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules.

Journal: European journal of medicinal chemistry

Published: December 19, 2019

15N-, 13C- and ¹H-NMR Spectroscopy Characterization and Growth Inhibitory Potency of a Combi-Molecule Synthesized by Acetylation of an Unstable Monoalkyltriazene.

15N-, 13C- and ¹H-NMR Spectroscopy Characterization and Growth Inhibitory Potency of a Combi-Molecule Synthesized by Acetylation of an Unstable Monoalkyltriazene.

Journal: Molecules (Basel, Switzerland)

Published: May 12, 2017

A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.

A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.

Journal: BMC cancer

Published: August 29, 2016

Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.

Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.

Journal: Bioorganic & medicinal chemistry letters

Published: July 27, 2016

Showing 1-10 of 10

Last Updated: 09/26/2026